Press release
Direct synthesis of novel antivirals
Model of deactivated HIV-protease, an essential enzyme of HIV
12. December 2006 (Saarbruecken/Emden, Germany) - Endotherm and PharmaInformatic today announced a collaboration to develop and optimise novel antiviral agents. PharmaInformatic, a company specialising in cheminformatics, will use it´s expert systems to predict antiviral and pharmacokinetic properties of novel compounds based on computer calculations. Promising drug candidates will be identified and directly synthesised by Endotherm.
The average cost of developing a new medicine is about 900 million US dollars and the whole process can take more than 12 years. A large part of research costs are spent on compounds that never make it to market because of insufficient ADME/Tox-properties. ADME/Tox stands for absorption, distribution, metabolism, excretion and toxicity.
ADME/Tox-properties are determined years after synthesis of an agent in clinical trials. The prediction of compound properties allows selection of those compounds with the best ADME/Tox-properties to become useful drugs, whereby efficiency of drug research is considerably increased early in the drug development process.
PharmaInformatic
Dr. Wolfgang Boomgaarden
Friesenstr. 36
Tel: +49 (0)4921-99 33 60
26721 Emden
Germany
Contact: http://www.pharmainformatic.com/html/contact_us.html
Endotherm GmbH
The company was founded in 1999 and provides exclusive synthesis of medicinally relevant compounds for the discovery and development of small molecule drugs. Endotherm’s customers include many of the world leading pharmaceutical companies, like Altana, Aventis, Bayer, Boehringer Ingelheim, Merck, Solvay, Schwarz Bioscience, Schering and Takeda. Further information: www.endotherm.de
PharmaInformatic
The company develops expert systems to optimise drug discovery and development. PharmaInformatic´s platform technology contains millions of substances together with experimental data and thousands of 3D-models of biomolecules. Proprietary methods based on cheminformatics and bioinformatics allow the prediction of pharmaceutical activity and pharmacological properties of a substance. Further information: www.pharmainformatic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Direct synthesis of novel antivirals here
News-ID: 13679 • Views: …
More Releases for Endotherm
Waste Heat Recovery System Market is expected to reach USD 113.8 Bn by 2030, as …
Waste Heat Recovery System Market size was valued at USD 70.83 Bn. in 2023 and the total Waste Heat Recovery System revenue is expected to grow by 7% from 2024 to 2030, reaching nearly USD 113.8 Bn.
𝐖𝐚𝐬𝐭𝐞 𝐇𝐞𝐚𝐭 𝐑𝐞𝐜𝐨𝐯𝐞𝐫𝐲 𝐒𝐲𝐬𝐭𝐞𝐦 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰
The Waste Heat Recovery System captures energy from various sources such as flue gases, diesel generators, and cooling tower steam. Known for its efficient methods in improving plant…
Waste Heat Recovery Systems Market Size | Share | Global Analysis 2022
The global waste heat recovery systems market size was valued at USD 66.3 billion in 2021 and is poised to grow at a significant CAGR of 6.3% during the forecast period 2022-28. Waste heat recovery systems are technologies that capture and reuse the heat generated by industrial processes or machinery that would otherwise be wasted. The market for waste heat recovery systems includes the development, manufacture, and sale of various…
Global Endotherm Knife Market Research scope, Methodology, Industry Chain Analys …
Introduction: An endotherm (from Greek “endon "within" and “ thermē "heat") is an organism that maintains its body at a metabolically favorable temperature, largely by the use of heat set free by its internal bodily functions instead of relying almost purely on ambient heat. A knife (plural knives) is a tool with a cutting edge or blade.
The global market size of Endotherm Knife is $$ million in 2017 with $$…
